USMLE Step 2 CK pulmonology & critical care questions

This patient has a mild-to-moderate asthma exacerbation (peak flow ≥70% predicted, able to speak in full sentences, no accessory muscle use). The initial treatment for any acute asthma exacerbation is repeated short-acting beta-agonist (albuterol) with an inhaled anticholinergic (ipratropium) to achieve rapid bronchodilation, along with systemic corticosteroids. Magnesium sulfate and noninvasive ventilation are reserved for severe or life-threatening exacerbations unresponsive to initial bronchodilator therapy. Arterial blood gas and imaging are not required before starting first-line bronchodilator therapy in a patient who is not in respiratory distress.

• A. Not indicated; there is no suspicion of pulmonary embolism from this presentation.
• B. Reserved for severe exacerbations with impending respiratory failure, not this mild-to-moderate presentation.
• D. Reserved as adjunct therapy for severe exacerbations refractory to inhaled bronchodilators.
• E. Blood gas is not required before starting first-line bronchodilators in a stable-appearing patient.

A silent chest in a patient with asthma indicates near-complete airflow obstruction with minimal air movement, not improvement, and combined with rising PaCO2, hypoxemia despite high-flow oxygen, and altered mental status/exhaustion, this represents impending respiratory failure. This is a clinical emergency requiring immediate endotracheal intubation and mechanical ventilation rather than continued escalation of medical therapy, which has already failed. Delaying definitive airway management in this setting risks cardiopulmonary arrest. Permissive hypercapnia and controlled hypoventilation strategies are then used to minimize barotrauma during ventilation.

• A. A beta-agonist already maximized by nebulizer would not address the need for airway protection in respiratory failure.
• B. Further bronchodilator escalation is inappropriate given evidence of respiratory failure and exhaustion.
• C. Inhaled corticosteroids have no role in acute severe exacerbations and would not address impending respiratory failure.
• E. Imaging would delay life-saving airway management and is not indicated acutely.

Exercise-induced bronchoconstriction is best prevented by inhaling a short-acting beta-agonist such as albuterol 15-20 minutes before exercise, which provides bronchodilation lasting through most exercise sessions. This approach is effective, convenient, and has a rapid onset appropriate for an identifiable trigger like scheduled practice. Daily controller therapy with ICS may be added if symptoms become frequent or if exercise is the only trigger but occurs very often, but it is not the first-line approach for isolated, predictable exercise-induced symptoms. Oral corticosteroids and epinephrine are not appropriate for routine prevention.

• A. Montelukast can be used but is less effective than SABA and is typically reserved for patients who cannot use inhaled therapy or need additional control.
• B. Epinephrine is not indicated for exercise-induced bronchoconstriction and carries unnecessary cardiovascular risk.
• C. Scheduled ICS without pre-exercise treatment is not the most direct or effective approach for isolated, predictable exercise-triggered symptoms.
• E. Oral corticosteroids are not used for routine prevention of exercise-induced bronchoconstriction due to systemic side effects.

This patient has an acute COPD exacerbation with increased dyspnea, sputum volume, and purulence (two of the three cardinal Anthonisen criteria), meeting criteria for antibiotic therapy. Standard management includes systemic corticosteroids (oral prednisone for 5 days) to reduce inflammation and shorten recovery time, plus an antibiotic covering typical pathogens such as Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis, in addition to bronchodilators and oxygen. ICU admission and intubation are not indicated since she is hemodynamically stable without severe respiratory distress or altered mental status. Pulmonary embolism workup is not warranted given her presentation is classic for infectious exacerbation.

• A. IV antibiotics and ICU admission are not warranted for a stable patient without severe respiratory failure.
• B. Corticosteroids should not be omitted since they reduce treatment failure and relapse in acute exacerbations.
• C. Her presentation is classic for an infectious exacerbation; CTPA is not indicated without signs suggesting embolism.
• E. Intubation is not indicated in a hemodynamically stable patient without severe respiratory distress or altered mentation.

Long-term home oxygen therapy is indicated in COPD patients with resting PaO2 ≤55 mm Hg or oxygen saturation ≤88% on room air, confirmed on at least two measurements over a 3-week period while clinically stable, regardless of the presence of cor pulmonale or polycythemia. This patient meets these criteria with a PaO2 of 54 mm Hg and repeated oxygen saturation of 87%. Long-term oxygen therapy (used at least 15 hours per day) has been shown to improve survival in hypoxemic COPD patients. Waiting for complications such as cor pulmonale or deferring treatment is not appropriate once criteria are met.

• A. Resting daytime hypoxemia criteria are already met; sleep oximetry is not required to justify therapy.
• C. Treatment should not be delayed once objective criteria for severe resting hypoxemia are met.
• D. Oxygen therapy should be started now because criteria are met, not deferred until cor pulmonale develops.
• E. His resting PaO2 already meets criteria for continuous home oxygen, not just exertional use.

Early-onset emphysema (before age 45) with a predominantly lower lobe, panacinar distribution in a nonsmoker, especially with a family history of early emphysema and associated liver disease, strongly suggests alpha-1 antitrypsin (AAT) deficiency. The most appropriate next step is to measure serum AAT level, which if low is followed by genotyping to confirm the diagnosis and identify the specific allele (such as ZZ). AAT deficiency causes unopposed neutrophil elastase activity in the lung parenchyma, leading to panacinar emphysema, while the misfolded protein accumulates in hepatocytes causing liver disease. Imaging has already established the pattern; sweat chloride and IgE testing are used for cystic fibrosis and allergic conditions, not this presentation.

• B. The CT pattern has already been described; repeating imaging with contrast will not establish the underlying diagnosis.
• C. Sweat chloride testing is used to diagnose cystic fibrosis, which does not match this presentation of emphysema with liver disease.
• D. Elevated IgE suggests allergic conditions such as allergic bronchopulmonary aspergillosis, not consistent with this presentation.
• E. Used to evaluate for tuberculosis, not indicated given this clinical picture of early emphysema with liver involvement.

High-resolution CT (HRCT) of the chest is the most accurate and appropriate initial imaging test when bronchiectasis is suspected clinically. It confirms the diagnosis by showing bronchial dilation, bronchial wall thickening, and loss of the normal tapering of airways (signet ring sign, tram-track lines). Chest x-ray is often normal or shows nonspecific findings and lacks the sensitivity to diagnose bronchiectasis. Once HRCT confirms bronchiectasis, further workup for an underlying cause (e.g., immunoglobulin levels, sweat chloride, alpha-1 antitrypsin) is pursued based on clinical context.

• A. Sputum culture helps identify causative organisms once bronchiectasis is diagnosed but does not establish the diagnosis itself.
• B. Bronchoscopy is reserved for evaluating focal lesions, obstruction, or obtaining microbiologic samples, not for initial diagnosis.
• C. Spirometry assesses the degree of airflow obstruction but cannot establish the anatomic diagnosis of bronchiectasis.
• E. Sweat chloride testing evaluates for cystic fibrosis as an underlying cause but is not the initial diagnostic test for bronchiectasis itself.

A reduced FEV1/FVC ratio (below 0.70) with a disproportionately reduced FEV1 relative to FVC defines an obstructive pattern, typically seen in COPD or asthma. The elevated total lung capacity (125% predicted) reflects air trapping and hyperinflation, which is characteristic of obstructive lung disease rather than restriction. In restrictive disease, both FEV1 and FVC are reduced proportionally with a preserved or increased FEV1/FVC ratio, and total lung capacity is decreased. This patient's findings are classic for COPD given the smoking history, reduced ratio, and hyperinflation.

• A. A mixed pattern requires evidence of reduced TLC in addition to a reduced ratio; this patient's TLC is increased, arguing against a restrictive component.
• B. Restrictive disease shows a low or normal FEV1/FVC ratio with reduced total lung capacity, not increased TLC as seen here.
• C. A diffusion defect alone does not explain the reduced FEV1/FVC ratio and increased TLC seen on this patient's spirometry.
• E. Extrathoracic obstruction produces a characteristic flattening of the inspiratory loop on flow-volume curves, not this ratio and volume pattern.

For a healthy outpatient with community-acquired pneumonia and no comorbidities or recent antibiotic use, the IDSA/ATS guidelines recommend monotherapy with amoxicillin as first-line therapy, as it provides excellent coverage against Streptococcus pneumoniae, the most common causative organism. Doxycycline or a macrolide (if local pneumococcal resistance is low) are acceptable alternatives. Respiratory fluoroquinolones and combination beta-lactam/macrolide therapy are reserved for outpatients with comorbidities or inpatients with more severe disease.

• A. Respiratory fluoroquinolones are reserved for patients with comorbidities or those at risk for drug-resistant pathogens, not healthy outpatients.
• B. Doxycycline is an acceptable alternative but is not preferred over amoxicillin as first-line therapy in a healthy outpatient per current guidelines.
• C. Piperacillin-tazobactam provides unnecessarily broad antipseudomonal coverage not indicated for a healthy outpatient with no risk factors.
• E. Combination therapy with a cephalosporin and macrolide is intended for inpatient treatment of CAP, not outpatient management of a healthy patient.

This patient has structural lung disease (bronchiectasis) and a prior isolation of Pseudomonas aeruginosa, both established risk factors for pseudomonal pneumonia, warranting empiric antipseudomonal coverage. Piperacillin-tazobactam, an antipseudomonal beta-lactam, combined with levofloxacin, an antipseudomonal fluoroquinolone with atypical coverage, provides appropriate broad empiric therapy. Standard CAP regimens such as ceftriaxone-azithromycin lack antipseudomonal activity and would be inadequate in this high-risk patient.

• B. Amoxicillin-clavulanate does not have reliable activity against Pseudomonas aeruginosa.
• C. Ampicillin-sulbactam lacks antipseudomonal activity, which is required given this patient's risk factors.
• D. Ceftriaxone does not cover Pseudomonas aeruginosa, making this regimen inadequate for this high-risk patient.
• E. Vancomycin targets MRSA, not Pseudomonas, and does not provide adequate gram-negative antipseudomonal coverage.

Hospital-acquired pneumonia (pneumonia occurring 48 hours or more after admission) in a setting with high rates of MRSA and multidrug-resistant gram-negative organisms requires empiric coverage against both pathogens. Vancomycin (or linezolid) covers MRSA, while cefepime provides antipseudomonal gram-negative coverage. Standard CAP regimens such as ceftriaxone-azithromycin are inadequate because they do not reliably cover MRSA or resistant gram-negative organisms encountered in the hospital setting.

• A. This regimen does not provide antipseudomonal or MRSA coverage needed in a hospital with high rates of resistant organisms.
• B. Macrolide monotherapy provides no coverage for MRSA or resistant gram-negative pathogens and is inadequate for hospital-acquired pneumonia.
• C. This regimen is designed for community-acquired pneumonia and lacks coverage for MRSA and resistant gram-negative organisms seen in hospital-acquired infections.
• D. Ampicillin-sulbactam alone does not cover MRSA or multidrug-resistant gram-negative organisms.

This patient's dysphagia from Parkinson disease, witnessed aspiration event, and subsequent development of fever with a right lower lobe infiltrate (the most gravity-dependent segment when aspiration occurs in the upright or semi-recumbent position) are classic for aspiration pneumonia. Risk factors include impaired swallowing, altered consciousness, and neurologic disease affecting airway protection. The causative organisms are typically oral flora, including anaerobes and streptococci, reflecting the source of aspirated material. The clinical and radiographic pattern here does not fit the other listed diagnoses.

• A. Pulmonary embolism with infarction would more likely present with pleuritic chest pain and a wedge-shaped infiltrate, without a preceding aspiration event.
• B. Bronchiolitis obliterans organizing pneumonia has a more subacute presentation and is not temporally linked to a witnessed aspiration event.
• C. Eosinophilic pneumonia is not associated with aspiration events and typically presents with peripheral or migratory infiltrates and peripheral eosinophilia.
• E. Hypersensitivity pneumonitis results from chronic antigen exposure and presents with a more insidious course, not an acute infiltrate following a witnessed aspiration event.

This patient's putrid sputum, cavitary lesion with air-fluid level, and risk factor of impaired consciousness (seizure after heavy alcohol use predisposing to aspiration) are classic for an anaerobic lung abscess. Ampicillin-sulbactam provides excellent coverage against oral anaerobes (including Bacteroides and Fusobacterium species) as well as aerobic oral flora, making it first-line therapy. Clindamycin is an alternative. Vancomycin, azithromycin, trimethoprim-sulfamethoxazole, and aztreonam all lack reliable anaerobic coverage needed to treat this polymicrobial infection.

• B. Azithromycin has limited activity against the anaerobic organisms typically responsible for lung abscess.
• C. Trimethoprim-sulfamethoxazole lacks reliable coverage against anaerobic oral flora implicated in lung abscess.
• D. Aztreonam covers aerobic gram-negative organisms but has no activity against anaerobes.
• E. Vancomycin targets gram-positive organisms including MRSA but does not provide adequate anaerobic coverage for a lung abscess.

PET/CT is the recommended next step in staging non-small cell lung cancer because it detects occult mediastinal lymph node involvement and distant metastases not seen on CT alone, which can change management from surgery to systemic therapy. If PET/CT shows abnormal mediastinal uptake, tissue sampling (mediastinoscopy or endobronchial ultrasound) is then needed to confirm nodal metastasis before ruling out surgery. Brain MRI is added for staging in stage II or higher NSCLC or if neurologic symptoms are present, but PET/CT is the appropriate initial whole-body staging step here. Bone scan is largely replaced by PET/CT for detecting bony metastases.

• A. Mediastinoscopy is invasive and is reserved for confirming nodal disease suggested by PET/CT or CT, not as the first staging step.
• B. Delaying with a repeat scan risks disease progression and does not address current staging needs.
• D. Bone scan is not first-line when PET/CT, which also evaluates bone, is available.
• E. Brain MRI is appropriate for more advanced stages or with neurologic symptoms, not as the initial staging test here.

Small cell lung cancer, identified here by the central mass and small round blue cells with scant cytoplasm, frequently secretes ectopic arginine vasopressin (ADH), causing the syndrome of inappropriate antidiuretic hormone secretion (SIADH). ADH acts on renal collecting duct V2 receptors to increase water reabsorption, producing euvolemic hyponatremia with inappropriately concentrated urine (urine osmolality greater than serum osmolality) and urine sodium above 40 mEq/L despite low serum sodium. This paraneoplastic syndrome is one of the most common in small cell lung cancer, along with Lambert-Eaton myasthenic syndrome. Management includes fluid restriction and treatment of the underlying tumor.

• A. Direct tubular invasion by a hilar mass is not a recognized mechanism of paraneoplastic hyponatremia.
• B. Excess ANP would cause natriuresis with volume depletion, not the euvolemic, concentrated-urine picture seen here, and is not the classic small cell lung cancer paraneoplastic syndrome.
• C. Adrenal insufficiency can cause hyponatremia but is not the typical paraneoplastic mechanism in small cell lung cancer and would usually present with hyperkalemia and hypotension.
• E. Hypercalcemia causing diabetes insipidus would cause hypernatremia from water loss, not hyponatremia, and is more typical of squamous cell carcinoma via PTHrP.

Superior vena cava syndrome results from extrinsic compression or invasion of the SVC, most commonly by a mediastinal mass from lung cancer, leading to impaired venous return from the head, neck, and upper extremities. Classic findings include facial and periorbital edema, facial plethora, and distended neck and chest wall collateral veins, with symptoms worsening when lying flat or bending forward due to increased venous pressure above the obstruction. Chest CT with contrast is used to confirm the diagnosis and define the mass and venous compression. Management involves tissue diagnosis of the underlying tumor, with stenting reserved for severe symptoms.

• B. Budd-Chiari syndrome is hepatic venous outflow obstruction causing ascites and lower body findings, unrelated to a mediastinal mass or facial swelling.
• C. Right heart failure causes systemic venous congestion but typically presents with lower extremity edema, hepatomegaly, and jugular venous distension without facial plethora or a mediastinal mass.
• D. Nephrotic syndrome causes generalized edema from hypoalbuminemia, not facial plethora with upper body venous distension tied to posture.
• E. Constrictive pericarditis causes systemic venous congestion but would not explain facial plethora or a mass-related obstructive picture, and imaging would show pericardial thickening, not a paratracheal mass.

A Pancoast tumor is a lung cancer arising in the superior sulcus (apex) of the lung that invades adjacent structures including the brachial plexus (causing C8-T1 distribution arm pain and intrinsic hand muscle weakness) and the sympathetic chain/stellate ganglion (causing Horner syndrome: ptosis, miosis, and anhidrosis). Rib destruction on imaging indicates local chest wall invasion. Diagnosis requires tissue biopsy, and staging with chest CT and PET/CT is needed before deciding on surgical resection, often combined with neoadjuvant chemoradiation. Smoking history and the apical opacity with rib destruction strongly support a primary lung malignancy over other causes.

• A. Thoracic outlet syndrome causes arm symptoms from vascular or neural compression but does not explain Horner syndrome or an apical mass with rib erosion.
• B. Brachial plexus neuritis is typically idiopathic and painful but lacks an associated lung mass, rib destruction, or Horner syndrome.
• D. Breast cancer metastasis to the lung apex is far less common than a primary Pancoast tumor in a heavy smoker with this presentation.
• E. Cervical disc herniation can cause arm pain but does not cause Horner syndrome or an apical lung opacity with rib destruction.

Idiopathic pulmonary fibrosis is diagnosed in an older adult with progressive dyspnea, bibasilar crackles, clubbing, and a restrictive pattern on PFTs (reduced FVC with preserved or increased FEV1/FVC ratio, reduced DLCO). The HRCT pattern of subpleural, basal-predominant reticulation with honeycombing and traction bronchiectasis, without ground-glass predominance, is the usual interstitial pneumonia (UIP) pattern that is diagnostic of IPF when other causes have been excluded. No identifiable cause such as connective tissue disease, drug exposure, or environmental antigen exposure is present, supporting the idiopathic classification. Surgical lung biopsy is unnecessary when HRCT shows a definite UIP pattern in the appropriate clinical context.

• A. Sarcoidosis typically shows upper-lobe predominant nodules and hilar lymphadenopathy, not basal honeycombing.
• B. Hypersensitivity pneumonitis typically shows ground-glass opacities, mosaic attenuation, and air trapping with a history of antigen exposure, not honeycombing without exposure history.
• C. COPD produces an obstructive pattern (reduced FEV1/FVC ratio) rather than the restrictive pattern seen here, and does not cause honeycombing.
• D. Nonspecific interstitial pneumonia usually shows ground-glass opacities with relative subpleural sparing and is more common in younger patients with connective tissue disease.

Sarcoidosis classically presents in young adults, more commonly Black women, with bilateral hilar lymphadenopathy on chest radiograph, erythema nodosum, and constitutional symptoms. Hypercalcemia occurs because granuloma macrophages express 1-alpha-hydroxylase, converting 25-hydroxyvitamin D to its active form 1,25-dihydroxyvitamin D, increasing intestinal calcium absorption independent of PTH. Elevated serum ACE, produced by granuloma epithelioid cells, supports the diagnosis but is neither sensitive nor specific enough alone; tissue biopsy showing non-caseating granulomas is needed for confirmation. This combination of bilateral hilar adenopathy, erythema nodosum, and hypercalcemia is a classic presentation (Löfgren-like picture) strongly suggestive of sarcoidosis.

• A. Lymphoma can cause mediastinal lymphadenopathy but typically presents with asymmetric or bulky nodal masses, B symptoms, and does not classically cause erythema nodosum or granuloma-mediated hypercalcemia.
• C. Tuberculosis typically causes unilateral or asymmetric lymphadenopathy with parenchymal infiltrates and cavitation, and hypercalcemia is uncommon.
• D. Histoplasmosis can cause mediastinal lymphadenopathy in endemic areas but is not classically associated with erythema nodosum or hypercalcemia in this pattern.
• E. Berylliosis mimics sarcoidosis pathologically but requires a specific occupational exposure history (aerospace, electronics, metal alloys), which is absent here.

Hypersensitivity pneumonitis, here from avian proteins in pigeon droppings and feathers (bird fancier's lung), results from a combined type III (immune complex) and type IV (delayed, cell-mediated/granulomatous) hypersensitivity response to repeatedly inhaled organic antigens. This produces lymphocytic and granulomatous inflammation in the small airways and alveoli, manifesting as ground-glass opacities, centrilobular nodules, and air trapping (mosaic attenuation) on HRCT. Symptom improvement away from the exposure source and positive precipitating (IgG) antibodies against the offending antigen support the diagnosis. Management requires antigen avoidance, with corticosteroids used for more severe or persistent symptoms.

• A. Isolated immune complex vasculitis is not the primary mechanism; hypersensitivity pneumonitis involves granulomatous interstitial and airway inflammation rather than vasculitis.
• B. Direct cytotoxic injury describes pneumoconioses from inert particulates like silica or asbestos, not an immune-mediated reaction to organic antigens.
• D. Type I hypersensitivity describes immediate allergic reactions such as asthma, not the subacute granulomatous lung disease described here.
• E. Autoantibody-mediated pneumocyte destruction is not the mechanism of hypersensitivity pneumonitis and is not supported by the findings described.

Asbestosis classically presents after a long latency (often 20-30 years) in workers exposed to asbestos fibers such as shipbuilders, insulators, and pipefitters. The hallmark imaging findings are lower lobe-predominant, subpleural reticular opacities with bilateral calcified pleural plaques, distinguishing it from silicosis. The restrictive pattern with reduced diffusing capacity confirms an interstitial fibrotic process. Pleural plaques are a specific marker of asbestos exposure and are not seen in silicosis.

• A. Silicosis typically shows upper lobe-predominant nodular opacities with egg-shell calcification of hilar lymph nodes, not pleural plaques, and occurs in miners or sandblasters.
• B. Chronic berylliosis occurs in workers exposed to beryllium (aerospace, electronics) and resembles sarcoidosis with hilar adenopathy, not pleural plaques.
• C. Hypersensitivity pneumonitis is associated with organic antigen exposure (birds, molds) and shows upper/mid-zone ground-glass or mosaic attenuation, not pleural plaques.
• D. Coal worker's pneumoconiosis causes upper lobe nodular opacities in coal miners, not pleural plaques or lower lobe fibrosis.

Amiodarone pulmonary toxicity typically develops after months of therapy and presents with subacute dyspnea, cough, and bilateral ground-glass or reticular opacities on CT. A characteristic but not universal finding is areas of increased parenchymal attenuation on CT due to the iodine content of amiodarone accumulating in macrophages. Management requires discontinuing amiodarone and, in moderate to severe cases, starting corticosteroids. Recognizing this adverse effect is essential because continued drug exposure can lead to progressive, potentially fatal pulmonary fibrosis.

• A. Pneumonia presents more acutely with fever and would not classically show high-attenuation parenchymal areas related to drug accumulation.
• C. Heart failure would be expected to show cardiomegaly, vascular redistribution, and effusions, and typically improves with diuresis, not a chronic fibrotic pattern.
• D. Cryptogenic organizing pneumonia is idiopathic by definition and would not be attributed to a specific causative drug exposure.
• E. Hypersensitivity pneumonitis is linked to organic antigen exposure, not a specific drug history, and lacks the high-attenuation CT finding.

Light's criteria classify an effusion as exudative if any one of the following is met: pleural fluid/serum protein ratio greater than 0.5, pleural fluid/serum LDH ratio greater than 0.6, or pleural fluid LDH greater than two-thirds the upper limit of normal serum LDH. Here, the protein ratio is 2.1/6.8 = 0.31 and the LDH ratio is 110/220 = 0.5, both below threshold, so none of the criteria are met. This fluid is therefore transudative, consistent with hepatic hydrothorax from cirrhosis-related portal hypertension. Transudative effusions result from altered hydrostatic or oncotic pressures rather than pleural or systemic inflammation.

• A. The protein ratio of 0.31 is below the 0.5 cutoff, so this criterion is not met.
• B. None of the three Light's criteria are satisfied by these values, so it cannot be classified as exudative by all three.
• C. The LDH ratio of 0.5 is below the 0.6 cutoff, so this criterion is not met.
• D. Cholesterol levels are a secondary criterion used only when Light's criteria give an equivocal result, which is not the case here.

This patient has an empyema, indicated by frankly purulent, foul-smelling fluid with pH below 7.2, glucose below 60 mg/dL, and organisms on Gram stain, along with loculation on imaging. Complicated parapneumonic effusions and empyemas require tube thoracostomy for adequate drainage in addition to antibiotics, since loculated infected fluid will not resolve with antibiotics alone. Delayed or inadequate drainage increases the risk of fibrothorax and prolonged illness. Intrapleural fibrinolytics or surgical decortication may be needed if simple tube drainage fails to resolve loculations.

• A. Antibiotics alone will not adequately clear infected pleural fluid once pH and glucose criteria for empyema are met.
• B. Simple thoracentesis is insufficient for loculated, purulent fluid, which requires continuous tube drainage.
• C. Observation risks progression to fibrothorax and sepsis in an established empyema.
• D. This patient requires inpatient drainage and intravenous therapy, not outpatient oral antibiotics.

This patient has clinical findings of tension pneumothorax: hypotension, tachycardia, hypoxia, tracheal deviation away from the affected side, absent breath sounds, jugular venous distention, and hyperresonance. Tension pneumothorax is a clinical diagnosis and a life-threatening emergency that requires immediate needle decompression (or finger thoracostomy) without waiting for imaging confirmation, followed by tube thoracostomy. Delaying treatment to obtain radiographic or CT confirmation can result in cardiovascular collapse and death. Definitive chest tube placement follows emergent decompression.

• A. Echocardiography is not the priority and delays definitive emergency intervention.
• B. Obtaining imaging before decompression delays life-saving treatment in a clinical emergency.
• C. Fluids alone will not relieve the obstructive physiology caused by tension pneumothorax; decompression is required.
• D. CT scanning is too time-consuming and unsafe in a hemodynamically unstable patient with an obvious clinical diagnosis.

In a patient with risk factors for malignancy (older age, significant smoking history, weight loss) presenting with a bloody exudative effusion, pleural fluid cytology is the best initial test to identify malignant cells and establish a diagnosis of malignant pleural effusion. Cytology has a diagnostic yield of 60-90% depending on the underlying tumor type, and if initial cytology is negative but suspicion remains high, pleural biopsy or thoracoscopy should follow. Hemorrhagic effusions in older smokers should always raise concern for an underlying malignancy such as lung cancer or mesothelioma.

• A. Adenosine deaminase is used to evaluate for tuberculous pleuritis, not malignancy.
• C. Amylase level is elevated in effusions related to pancreatitis or esophageal rupture, not malignancy.
• D. pH alone is used to assess for complicated parapneumonic effusion/empyema, not to diagnose malignancy.
• E. Triglyceride level is used to diagnose chylothorax, which is not suggested by this presentation.

In patients with a high pretest probability for pulmonary embolism based on Wells score (greater than 6 points), D-dimer testing should not be performed because a negative result would not reliably exclude PE and could lead to dangerous delays in treatment. These patients should proceed directly to CT pulmonary angiography, the most accurate and widely available test for diagnosing PE, since it can both confirm the diagnosis and assess clot burden. D-dimer is reserved for low to moderate pretest probability to help rule out PE without imaging. Anticoagulation should be initiated promptly if CTPA confirms the diagnosis or if imaging will be delayed.

• A. Echocardiography can assess for right heart strain in confirmed or massive PE but is not the diagnostic test of choice for suspected PE.
• B. D-dimer has low specificity and is not useful in high pretest probability patients since a negative result does not exclude PE.
• D. Isolated lower extremity ultrasound could support a diagnosis of DVT but would not definitively diagnose or exclude PE itself.
• E. V/Q scan is reserved for patients who cannot undergo CT angiography, such as those with contrast allergy or renal impairment.

After systemic thrombolysis for massive PE, anticoagulation should be continued or resumed to prevent further clot propagation and recurrence. Unfractionated heparin is preferred immediately post-thrombolysis because it is easily titratable and rapidly reversible, and it is typically started without a bolus to minimize bleeding risk given the recent thrombolytic exposure. Once the patient is stable and bleeding risk has decreased, transition to a direct oral anticoagulant or warfarin can occur. Repeating thrombolysis or escalating to surgery is unnecessary once hemodynamic stability has been restored.

• A. Surgical embolectomy is reserved for patients who are refractory to or ineligible for thrombolysis, not a patient who has already improved.
• B. An IVC filter is reserved for patients with a contraindication to anticoagulation, not as routine next step after successful thrombolysis.
• C. Oral anticoagulants are not used as initial therapy in the acute setting after thrombolysis; parenteral anticoagulation is required first.
• E. The patient has already responded hemodynamically, so repeat thrombolysis adds bleeding risk without clear benefit.

This patient's pulmonary embolism is provoked by a major transient risk factor, recent major orthopedic surgery, which carries a high but reversible risk of recurrence. Current guidelines recommend a finite course of anticoagulation, typically 3 months, for provoked VTE due to a transient major risk factor, since the precipitating cause has resolved. In contrast, unprovoked VTE or VTE associated with persistent risk factors (such as active cancer or antiphospholipid syndrome) warrants extended or indefinite anticoagulation after reassessing bleeding risk. Stopping anticoagulation at discharge or treating for a shorter period would leave a substantial residual clot burden and risk of recurrence.

• A. Twelve months is excessive for a provoked VTE with a clearly reversible precipitant.
• B. Stopping at discharge is insufficient treatment duration and would risk early recurrence or extension of thrombus.
• C. Indefinite anticoagulation is reserved for unprovoked VTE or persistent risk factors, not a single provoked event.
• E. Six months exceeds the standard duration recommended for VTE provoked by a major transient risk factor.

This patient has an acute VTE but an absolute contraindication to anticoagulation due to recent neurosurgery and high intracranial bleeding risk. In this setting, an inferior vena cava filter is indicated to prevent further embolization of lower extremity clot to the pulmonary circulation while the bleeding risk remains prohibitive. Anticoagulation should be resumed once the contraindication resolves, since the filter alone does not treat the thrombus or prevent its propagation. Thrombolysis and any form of anticoagulation are contraindicated in the immediate postoperative neurosurgical period.

• A. Thrombolytics would markedly worsen the risk of intracranial hemorrhage and are contraindicated.
• C. Unfractionated heparin is contraindicated given the recent craniotomy and high bleeding risk.
• D. Warfarin requires therapeutic anticoagulation, which is contraindicated in this patient.
• E. Subcutaneous enoxaparin still carries unacceptable bleeding risk in this postoperative neurosurgical setting.

Transthoracic echocardiography is the appropriate initial test when pulmonary hypertension is suspected, as it estimates pulmonary artery systolic pressure, assesses right ventricular size and function, and screens for left heart disease as an alternative cause. Right heart catheterization is the gold standard and is required to confirm the diagnosis and measure pulmonary vascular resistance, but it is performed after noninvasive screening raises sufficient suspicion. Scleroderma is a recognized risk factor for pulmonary arterial hypertension, making echocardiographic screening particularly important in this population. CT chest and PFTs help evaluate for interstitial lung disease as a contributing cause but do not establish the diagnosis of pulmonary hypertension itself.

• A. Right heart catheterization is the confirmatory test but should follow, not precede, echocardiographic screening.
• C. CT chest helps assess for interstitial lung disease but does not quantify pulmonary artery pressures.
• D. A V/Q scan is used to evaluate for chronic thromboembolic pulmonary hypertension after pulmonary hypertension has already been identified.
• E. Pulmonary function testing assesses for an underlying lung disease contribution but does not diagnose pulmonary hypertension.

Polysomnography is the gold-standard diagnostic test for obstructive sleep apnea, recording respiratory events, oxygen desaturations, EEG-based sleep staging, and arousals to calculate the apnea-hypopnea index. A diagnosis of OSA requires an AHI of 5 or more events per hour accompanied by symptoms, or an AHI of 15 or more regardless of symptoms. Home sleep apnea testing is an acceptable alternative in patients with a high pretest probability and no significant comorbidities, but in-lab polysomnography remains the most accurate confirmatory test. Screening tools such as the Epworth Sleepiness Scale support clinical suspicion but cannot establish the diagnosis.

• A. The Epworth Sleepiness Scale is a subjective screening questionnaire for daytime sleepiness, not a diagnostic test.
• B. Pulse oximetry alone can suggest desaturations but cannot quantify the apnea-hypopnea index needed for diagnosis.
• D. Arterial blood gas analysis may show chronic hypercapnia in severe cases but does not diagnose OSA.
• E. Pulmonary function testing evaluates for obstructive or restrictive lung disease, not sleep-disordered breathing.

Continuous positive airway pressure is first-line therapy for moderate to severe obstructive sleep apnea, as it splints the upper airway open during sleep, preventing collapse and resolving apneic and hypopneic events. CPAP improves daytime symptoms, reduces cardiovascular risk associated with OSA, and is more effective than oral appliances, which are generally reserved for patients with mild OSA or those who cannot tolerate CPAP. Surgical options like uvulopalatopharyngoplasty are reserved for patients with anatomic obstruction who fail or cannot tolerate CPAP. Weight loss is also recommended as an adjunct but does not replace CPAP as initial therapy in symptomatic moderate to severe disease.

• A. Oral appliances are an alternative for mild OSA or CPAP-intolerant patients, not first-line for moderate to severe disease.
• B. Supplemental oxygen alone does not relieve the upper airway obstruction causing apneic events.
• C. Modafinil may be used for residual daytime sleepiness despite adequate CPAP therapy, not as initial treatment.
• D. Surgery is considered after failure of or intolerance to CPAP, not as first-line therapy.

Obesity hypoventilation syndrome is defined by obesity (BMI of 30 kg/m² or greater), daytime hypercapnia (PaCO2 above 45 mmHg) with compensatory metabolic alkalosis, and sleep-disordered breathing, after other causes of hypoventilation have been excluded. Most patients with OHS also have coexisting obstructive sleep apnea, as in this patient, but OSA alone does not typically cause awake daytime hypercapnia. The restrictive pattern on pulmonary function testing reflects the mechanical burden of obesity on the chest wall and diaphragm rather than obstructive airway disease. A normal FEV1/FVC ratio argues against COPD as the cause of the hypercapnia.

• B. Primary alveolar hypoventilation (Ondine's curse) occurs without obesity or obstructive sleep apnea and is a diagnosis of exclusion unrelated to this presentation.
• C. Central sleep apnea is characterized by absent respiratory effort during apneas, not the obstructive pattern and obesity seen here.
• D. The normal FEV1/FVC ratio excludes an obstructive process such as COPD as the explanation for hypercapnia.
• E. OSA alone causes nocturnal desaturations and apneas but does not typically produce chronic awake daytime hypercapnia.

The Berlin definition of ARDS requires onset within 1 week of a known clinical insult, bilateral opacities on chest imaging not fully explained by effusion or collapse, respiratory failure not explained by cardiac failure or fluid overload, and a PaO2/FiO2 ratio ≤300 on at least 5 cm H2O of PEEP or CPAP. This patient's ratio is 72/0.6 = 120 mmHg, consistent with moderate ARDS, triggered by the systemic inflammatory response from pancreatitis. The normal echocardiogram and low BNP exclude a cardiogenic cause. Acute pancreatitis is a well-recognized indirect precipitant of ARDS through systemic inflammation and increased capillary permeability.

• A. There is no prior history of interstitial lung disease or fibrotic imaging pattern described.
• B. The diffuse bilateral pattern and systemic inflammatory trigger favor ARDS over infectious consolidation.
• D. Embolism would not typically cause bilateral diffuse infiltrates or this degree of hypoxemia pattern.
• E. Normal ejection fraction and low BNP make a cardiac cause of pulmonary edema unlikely.

Lung-protective ventilation for ARDS uses low tidal volumes (6 mL/kg predicted body weight) to limit plateau pressure to ≤30 cm H2O, reducing ventilator-induced lung injury from alveolar overdistension. This patient's tidal volume of 10 mL/kg and plateau pressure of 32 cm H2O exceed safe limits. The resulting mild respiratory acidosis from permissive hypercapnia is an accepted trade-off when reducing tidal volume, as demonstrated by the ARMA trial showing mortality benefit with the low tidal volume strategy. Rate can be adjusted modestly to manage CO2, but the priority is correcting the injurious tidal volume first.

• A. Pressure-controlled ventilation with higher pressures would worsen the risk of barotrauma, not reduce it.
• B. Excessive PEEP escalation without addressing tidal volume does not correct the overdistension causing elevated plateau pressure.
• C. Increasing FiO2 does not address the ventilator-induced lung injury risk from high tidal volume.
• E. Increasing rate does not address the primary problem of excessive tidal volume and plateau pressure.

In patients with severe ARDS (PaO2/FiO2 <150 mmHg) who remain hypoxemic despite optimized lung-protective ventilation, prone positioning for at least 12-16 hours per day improves oxygenation and reduces mortality by promoting more uniform distribution of ventilation and perfusion, recruiting dorsal lung regions, and reducing ventilation-perfusion mismatch. The PROSEVA trial demonstrated a significant mortality benefit with early prone positioning in severe ARDS. It should be considered before more experimental or less evidence-supported rescue therapies.

• A. High-dose corticosteroids are not established first-line rescue therapy for refractory hypoxemia in this setting.
• B. Further escalating PEEP beyond this level increases barotrauma risk without the proven mortality benefit of proning.
• D. Inhaled nitric oxide may transiently improve oxygenation but has not shown a mortality benefit and is not the preferred next step.
• E. High-frequency oscillatory ventilation has been shown to increase mortality in ARDS and is no longer recommended.

Type 2 (hypercapnic) respiratory failure results primarily from alveolar hypoventilation, in which reduced minute ventilation relative to metabolic CO2 production causes CO2 retention, as reflected by this patient's markedly elevated PaCO2 of 78 mmHg and acute-on-chronic respiratory acidosis. In COPD, hypoventilation occurs from increased work of breathing, respiratory muscle fatigue, and blunted central respiratory drive, often worsened by excess supplemental oxygen suppressing hypoxic drive. This contrasts with type 1 (hypoxemic) respiratory failure, which is driven by V/Q mismatch, shunt, or diffusion impairment with a normal or low PaCO2. The hallmark distinguishing feature is the markedly elevated PaCO2 with hypoventilation as the dominant mechanism.

• A. V/Q mismatch is the dominant mechanism in type 1 hypoxemic failure, not the primary driver of this patient's hypercapnia.
• C. Dead space increase from vascular obstruction, as in pulmonary embolism, is not the mechanism in this COPD exacerbation.
• D. Diffusion impairment classically causes isolated hypoxemia without significant CO2 retention since CO2 diffuses more readily.
• E. Shunting causes refractory hypoxemia unresponsive to supplemental oxygen, not the hypercapnia and hypoventilation seen here.

This patient meets criteria for septic shock from a urinary source, with hypotension, elevated lactate (4.2 mmol/L), and altered mental status. The Surviving Sepsis Campaign guidelines recommend rapid administration of at least 30 mL/kg of balanced crystalloid within the first 3 hours for hypotension or lactate ≥4 mmol/L, given promptly alongside early broad-spectrum antibiotics, which have already been started. Source control and imaging can follow once resuscitation is underway, but should not delay initial fluid resuscitation. Vasopressors are added if hypotension persists despite adequate fluid resuscitation, not as an immediate first step before a fluid trial.

• A. Transfusion is not indicated here since there is no evidence of significant anemia or bleeding driving the shock.
• B. Vasopressors are indicated for persistent hypotension after adequate fluid resuscitation, not as the initial step, and peripheral administration carries extravasation risk.
• D. Hydrocortisone is reserved for septic shock with ongoing vasopressor requirement despite fluids and vasopressors, not as initial therapy.
• E. Imaging for source control should not delay the initial fluid bolus in a hemodynamically unstable patient.

Norepinephrine is the first-line vasopressor for septic shock per Surviving Sepsis Campaign guidelines, chosen for its potent alpha-1 mediated vasoconstriction with modest beta-1 inotropic effect, which raises mean arterial pressure while causing less tachyarrhythmia than dopamine. The goal is a mean arterial pressure of at least 65 mmHg. If the target is not achieved with norepinephrine alone, vasopressin or epinephrine can be added as a second agent. Dopamine is associated with more arrhythmias and worse outcomes compared with norepinephrine in septic shock and is no longer first-line.

• A. Vasopressin is used as an add-on agent to norepinephrine, not as first-line monotherapy for septic shock.
• C. Dobutamine is an inotrope used for cardiogenic shock or low cardiac output states, not as primary therapy for septic shock hypotension.
• D. Phenylephrine lacks inotropic activity and is typically reserved for specific situations such as tachyarrhythmia limiting norepinephrine use.
• E. Dopamine is associated with increased arrhythmias and higher mortality compared with norepinephrine and is not first-line.

This patient's hemodynamic profile, elevated central venous pressure, low cardiac output, and elevated systemic vascular resistance, combined with jugular venous distention and distant heart sounds after blunt chest trauma, is classic for obstructive shock from pericardial tamponade. Blood accumulating in the pericardial sac restricts diastolic filling, raising venous pressures while limiting stroke volume and cardiac output, triggering compensatory vasoconstriction. Hypovolemic shock would show low central venous pressure rather than elevated, and cardiogenic shock from contusion typically does not produce the acute jugular venous distention and distant heart sounds seen here. Equal, clear breath sounds help exclude a tension pneumothorax as the obstructive cause.

• B. Septic shock presents with low systemic vascular resistance and typically low central venous pressure early on, not elevated CVP with high SVR.
• C. Hypovolemic shock presents with low central venous pressure and low systemic vascular resistance is typically compensatory but CVP would be low, not elevated as seen here.
• D. Neurogenic shock from spinal injury causes low systemic vascular resistance with bradycardia, not the tachycardia and elevated SVR seen here.
• E. Myocardial contusion can impair contractility but would not typically produce jugular venous distention and distant heart sounds this acutely.

This patient demonstrates Beck triad, hypotension, jugular venous distention, and muffled heart sounds, along with pulsus paradoxus, an inspiratory drop in systolic blood pressure exceeding 10 mmHg. In malignant pericardial effusion, fluid accumulation restricts ventricular filling; inspiration increases venous return to the right heart, causing the interventricular septum to shift leftward and reduce left ventricular filling and stroke volume, producing the exaggerated fall in systolic pressure. Clear lung fields argue against decompensated heart failure as the primary process, and the gradual onset over a week with normal breath sounds is inconsistent with tension pneumothorax. Confirmatory diagnosis is made with echocardiography showing pericardial effusion with chamber collapse.

• A. Pulmonary embolism can cause hypotension and tachycardia but does not typically produce muffled heart sounds or pronounced pulsus paradoxus.
• B. Tension pneumothorax presents with absent breath sounds on the affected side and acute respiratory distress, not clear bilateral lung fields.
• C. Constrictive pericarditis presents with signs of venous congestion but Beck triad and significant pulsus paradoxus are characteristic of tamponade, not constriction.
• E. Decompensated heart failure typically presents with pulmonary crackles and does not characteristically produce pulsus paradoxus with distant heart sounds.

This patient has a depressed level of consciousness (unable to protect his airway, absent gag reflex), hypercapnic respiratory failure (PaCO2 68 mmHg with acidemia), and hypoxemia despite supplemental oxygen, all classic indications for endotracheal intubation. Airway protection takes priority over diagnostic workup in a patient who cannot maintain or protect his own airway. Noninvasive ventilation is contraindicated in patients with altered mental status and absent airway protective reflexes because of aspiration risk. Definitive airway management must precede further diagnostic or antidotal measures once the airway is deemed unsafe.

• A. Head imaging may be indicated later but securing the airway takes priority in an unresponsive patient with absent gag reflex and respiratory failure.
• B. Flumazenil is not indicated without confirmed benzodiazepine overdose and risks precipitating seizures; it does not address the unprotected airway.
• D. A nasopharyngeal airway does not protect against aspiration or provide definitive ventilatory support in this setting.
• E. Noninvasive ventilation is contraindicated in a patient with absent airway protective reflexes and depressed consciousness due to aspiration risk.

A rise in peak pressure with an unchanged plateau pressure indicates a problem with airway resistance rather than lung or chest wall compliance, since plateau pressure reflects static alveolar pressure after flow has stopped. Common causes include retained secretions, bronchospasm, biting the tube, or a kinked circuit, all of which increase resistive pressure without affecting the compliance-dependent plateau pressure. The combination of rhonchi and tube biting strongly suggests secretions as the cause here. In contrast, conditions that reduce lung or chest wall compliance (edema, pneumothorax, consolidation) raise both peak and plateau pressures together.

• A. Tension pneumothorax decreases compliance and would increase both peak and plateau pressures, along with hemodynamic instability and absent breath sounds on one side.
• B. Reduced chest wall compliance raises both peak and plateau pressures equally, which is not seen here.
• D. Mainstem intubation causes decreased compliance of the ventilated lung and would raise both peak and plateau pressures, with asymmetric breath sounds.
• E. Pulmonary edema reduces lung compliance and would raise both peak and plateau pressures, not peak pressure alone.

This patient meets standard readiness criteria for weaning: hemodynamic stability without vasopressors, adequate oxygenation (PaO2/FiO2 ratio well above 150-200) on low FiO2 and PEEP, normal acid-base status, intact mental status, and an effective cough with manageable secretions. The next step is a spontaneous breathing trial (e.g., low-level pressure support or T-piece for 30-120 minutes) to directly assess the patient's ability to tolerate unassisted breathing before extubation. Passing a spontaneous breathing trial is the best predictor of successful extubation. There is no indication to escalate ventilatory support or obtain further imaging when the patient already meets clinical weaning criteria.

• A. The patient is already alert and following commands, so sedation is not an ongoing issue; the priority is to test spontaneous breathing capacity.
• C. Increasing PEEP is not indicated given already adequate oxygenation and would not address weaning readiness.
• D. Returning to full ventilatory support is unnecessary and would delay weaning in a patient who meets readiness criteria.
• E. Routine CT imaging is not required to assess weaning readiness when clinical and gas exchange criteria are already met.

The pH is near-normal (7.36) despite a markedly elevated PaCO2 (58 mmHg), with a compensatory elevation in HCO3- (32 mEq/L), consistent with chronic respiratory acidosis that has undergone renal metabolic compensation over time. In chronic CO2 retention, the kidneys retain bicarbonate to normalize pH, which takes days, distinguishing it from acute respiratory acidosis where pH would be markedly low with only minimal bicarbonate rise. The patient's stable clinical presentation without acute distress supports a chronic, compensated process rather than an acute decompensation. This pattern is classic for a patient with longstanding COPD and chronic CO2 retention.

• B. Metabolic alkalosis would show an elevated pH, not a near-normal pH with elevated PaCO2 as the primary driver.
• C. A mixed acidosis would show a lower pH with insufficient bicarbonate elevation relative to the CO2 rise, not a near-normal pH.
• D. There is no evidence of acute decompensation (stable symptoms, near-normal pH) or additional metabolic acidosis, which would lower the pH further.
• E. Acute respiratory acidosis would show a markedly low pH since renal compensation takes days and has not yet occurred.

The rapid onset after a known food allergen exposure, combined with urticaria, angioedema (lip swelling), stridor, wheezing, hypotension, and tachycardia, fulfills clinical criteria for anaphylaxis involving skin, respiratory, and cardiovascular systems. This multisystem presentation distinguishes anaphylaxis from isolated angioedema or an airway infection. Immediate recognition is critical because anaphylaxis can progress rapidly to complete airway obstruction and cardiovascular collapse without prompt treatment with intramuscular epinephrine. Food triggers, particularly shellfish, are among the most common causes of anaphylaxis.

• A. Aspiration pneumonitis would present with a history of vomiting or impaired consciousness and would not cause urticaria or hypotension of this acute onset.
• B. Acute epiglottitis typically presents with fever, sore throat, and muffled voice over hours, not urticaria and hypotension immediately after food exposure.
• C. Vocal cord dysfunction causes stridor without urticaria, hypotension, or a temporal link to allergen exposure.
• D. ACE inhibitor-induced angioedema causes lip and tongue swelling without urticaria, wheezing, or hypotension, and there is no history of ACE inhibitor use here.

Carbon monoxide poisoning should be treated immediately with 100% high-flow oxygen via non-rebreather mask, which accelerates dissociation of carbon monoxide from hemoglobin and shortens the carboxyhemoglobin half-life. Pulse oximetry is unreliable in carbon monoxide poisoning because it cannot distinguish carboxyhemoglobin from oxyhemoglobin, explaining the falsely normal saturation despite significant toxicity. Hyperbaric oxygen therapy may be considered for patients with severe toxicity (loss of consciousness, carboxyhemoglobin above 25%, cardiac ischemia, or pregnancy) but only after initial stabilization with normobaric oxygen and further evaluation, not as the very first step. The patient's confusion is explained by hypoxic injury from carbon monoxide and does not itself mandate intubation.

• B. Hyperbaric oxygen may ultimately be indicated given the severity, but 100% normobaric oxygen should be started immediately while arranging transfer and further assessment.
• C. Chest radiography does not address the immediate life threat of carbon monoxide toxicity and should not delay oxygen administration.
• D. Methemoglobinemia is a separate condition and there is no clinical indication here (such as cyanosis unresponsive to oxygen) to suggest it.
• E. The patient is confused but has a patent airway and adequate respirations; intubation is not indicated based on the information given.

Fat embolism syndrome classically occurs 24-72 hours after long bone or pelvic fracture and presents with the triad of hypoxemia, neurologic changes (confusion), and a petechial rash typically over the chest, axillae, and conjunctivae, often accompanied by thrombocytopenia and fever. The mechanism involves marrow fat globules entering venous circulation after fracture or intramedullary instrumentation, causing microvascular occlusion and a systemic inflammatory response in the lungs, brain, and skin. Chest imaging characteristically shows bilateral pulmonary infiltrates similar to ARDS. Management is supportive, as there is no specific antidote, and early fracture stabilization reduces risk.

• A. Pneumonia would not explain the petechial rash or the temporal relationship to the fracture and intramedullary nailing.
• C. There is no source of sepsis described, and the classic triad of fever, neurologic change, and petechiae after long bone fracture points to a specific syndrome rather than generic ARDS.
• D. Pulmonary thromboembolism typically causes pleuritic chest pain and does not explain the petechial rash, thrombocytopenia, or confusion in this pattern.
• E. There is no history of recent blood product transfusion provided in this vignette.

Transfusion-associated circulatory overload (TACO) presents with hypertension, jugular venous distension, an S3 gallop, and a markedly elevated BNP in a patient with preexisting cardiac dysfunction, reflecting volume overload from the transfused product. This contrasts with transfusion-related acute lung injury (TRALI), which typically causes hypotension (not hypertension), normal cardiac filling pressures, and a normal or only mildly elevated BNP, resulting from donor antibody-mediated neutrophil activation in the recipient's lungs. Both conditions can present with acute dyspnea, hypoxemia, and bilateral infiltrates within 6 hours of transfusion, making the hemodynamic profile and BNP essential to distinguish them. Management of TACO includes diuresis, whereas TRALI is managed with supportive respiratory care without diuretics.

• B. TRALI typically presents with hypotension and a normal BNP, not hypertension with jugular venous distension and markedly elevated BNP as seen here.
• C. Acute hemolytic transfusion reaction presents with fever, flank pain, hemoglobinuria, and signs of hemolysis, not isolated pulmonary edema with elevated BNP.
• D. Delayed hemolytic transfusion reactions occur days later with gradual hemoglobin decline and jaundice, not acute dyspnea with pulmonary edema on imaging.
• E. Anaphylactic transfusion reactions present with urticaria, hypotension, and bronchospasm, typically within minutes of transfusion onset, not volume overload findings.